The world’s first RNA-based cancer drug has revealed promising results according to a peer-reviewed study in the scientific journal Advanced Materials. Overall, the report states that this new drug, tested on mice, has the potential to boost the effectiveness of both chemotherapy and immunotherapy – or, in this case, the combined treatments called chemo-immunotherapy. The … Read more
Triple-Negative Breast Cancer (TNBC) is an aggressive form of breast cancer which spreads and grows rapidly in the body. Approximately 10-15% of all breast cancers are TNCB, named triple-negative for its negative testing of three molecular components – estrogen, progesterone, and human epidermal growth factor (HER2). This cancer is more likely to return than other … Read more
Every day, there are millions of women around the world who are at risk of getting ovarian cancer – many don’t know they are at risk, while a small percentage are unaware that they already have it. However, in the past few years, science has continued to lead the way through medical research and advancements … Read more
We are very passionate about sponsoring the Israel Cancer Association’s Prevention GENEration Program in collaboration with The Israel Hereditary Breast and Ovarian Cancer Consortium. The aim of the program is to reduce cancer morbidity in Israel by promoting research, prevention, early detection, treatment modalities, and means of rehabilitation. The High Rate of Individuals with the … Read more
A new blood test known as Signatera has shown incredible ability to detect cancer relapses long before traditional scans, making it a game changer for patients.
The President of the American Society for Clinical Oncology shared that new research has found that the Lynparza parp inhibitor could have a significant impact on the treatment and decision paths of patients with both high-risk and early-stage breast cancer. The study also showed that Lynparza reduces the chances that patients with the BRCA gene … Read more
Researchers at Tel Aviv University have successfully treated cancer in mice using gene-editing CRISPR technology.
Researchers from the Moffitt Cancer Center have developed a deep learning model that can identify the course of treatment for certain types of lung cancer.